21 July 2021 15:50 BST
Transaction by Person Discharging Managerial Responsibilities
AstraZeneca PLC (the Company) announced that on 21 July 2021, Marc Dunoyer, Chief Financial Officer, received 21,243 Ordinary Shares of $0.25 each in the Company (Ordinary Shares). The Ordinary Shares were issued to Mr Dunoyer on completion of the Company's acquisition of Alexion Pharmaceuticals, Inc. (Alexion) as part consideration for the 20,000 Alexion shares held by Mr Dunoyer at the time of completion.
In accordance with the Agreement and Plan of Merger entered into by the Company on 12 December 2020, as consideration for each Alexion share held on completion of the acquisition, being 21 July 2021, Alexion shareholders received $60 in cash and, at their election, either 2.1243 AstraZeneca American Depositary Shares (each representing one half of an Ordinary Share) or the Ordinary Share equivalent.
|PDMR||Nature of the transaction||Quantity of Ordinary Shares received||Estimated valuation of price per Ordinary Share|
|Marc Dunoyer||Ordinary Shares issued in consideration for the acquisition of Alexion Pharmaceuticals, Inc.||21,243||US$115.08|
The attached notification, made in accordance with the requirements of the EU and UK Market Abuse Regulations, gives further detail.
|1||Details of the person discharging managerial responsibilities / person closely associated|
|2||Reason for the notification|
|a)||Position/status||Chief Financial Officer|
|b)||Initial notification /Amendment||Initial notification|
|3||Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor|
|4||Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted|
|a)||Description of the financial instrument, type of instrument Identification code||Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292|
|b)||Nature of the transaction||Ordinary Shares issued in consideration for the acquisition of Alexion Pharmaceuticals, Inc.|
|c)||Price(s) and volume(s)||
|d)||Aggregated information - Aggregated volume - Price||Not applicable - single transaction|
|e)||Date of the transaction||21 July 2021|
|f)||Place of the transaction||Outside a trading venue|
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact firstname.lastname@example.org or visit www.rns.com.